Endocrine Abstracts

Introduction: Prolactinomas are the most common tumors among functional pituitary adenomas and they constitute 40% of all pituitary tumors. Dopamine agonists (DA) are considered the primary treatment of prolactinoma. DA can lead to complete remission (including eradicacion of the tumor), allowing discotinuation of treatment. So far, there aren’t clinical criteria with sufficient predictive value for long-term remission.Objective: To assess the effec...

Gliomas are derived from glial-cells and are the most common primary brain tumor, characterized by rapid growth and invasion. Astrocytomas are a subset of malignant gliomas which are classified, based on their agresiveness features, in low grades (I and II) to high grades (HGAs; III and IV), being grade-IV (glioblastoma multiforme; GBM) the most malignant and aggressive type. Current standard treatment for GBMs consists on surgery followed by radiotherapy/chemotherapy; however...

Background: Gliomas are the most common primary brain tumor, being astrocytomas a subset of malignant gliomas graded on a scale of I to IV. Grade-IV astrocytomas (glioblastoma multiforme; GBM) are the most malignant and aggressive type. Current standard treatments are ineffective, being their average postoperative survival of 12-16 months. Therefore, there is a clear need for the identification of novel therapeutic targets to treat this pathology. In this context, the truncate...

Influence of Diabesity in the visceral adipose tissue miRNA expression profile.Background: The term diabesity arose in 2001 to refer to the coexistence of obesity (OB) and type 2 diabetes (T2D). It is estimated that 89% of adults diagnosed with T2D have a BMI greater than 25 kg/m2, and of them, 45% are obese. However, the mechanisms because why some obese patients develop T2D and other do not, are still unclear.Objective...

Background: the treatment of individuals with type 1 diabetes (T1D) has significantly evolved in recent years. Therefore, with the aim of achieving glycaemic targets to prevent or slow down the progression of the disease and its complications, hybrid closed-loop systems (AID) have been developed. These systems integrate three components: a continuous real-time glucose monitor, a control algorithm and an insulin pump. The objective of this study is to analyse the glycaemic and ...

Introduction: Approximately 20% of neuroendocrine tumor (NET) patients experience carcinoid syndrome (CS), primarily associated with metastatic ileal NETs. CS manifests with symptoms such as diarrhea, flushes, and cardiac complications. Carcinoid heart disease (CHD) is a negative prognostic factor in NETs. However, the considerable variability in reported diagnoses and treatment approaches in the literature creates uncertainty about optimal management in this specific populati...

Corticotroph tumours, comprising around 15% of pituitary tumours, express ACTH and other peptides originating from TPIT-lineage adenohypophyseal cells. Their tumorigenesis involves a complex interplay of genetic and epigenetic factors and hormonal and growth factor stimulation. Silent corticotroph tumours (SCT) share immunopositivity for ACTH and TPIT with functioning corticotroph tumours (FCT) but do not exhibit evidence of hypercortisolism. Despite their aggressive growth an...

Background: Hypophosphatemic rickets are disabling conditions that negatively impact physical functioning, activities of daily living, mental health, social life, and leisure activities. The most common cause of Hypophosphatemic rickets is genetic factors, such as X-linked hypophosphatemia. The evaluation of the scientific application of familial hypophosphatemic rickets aids in understanding the research landscape, identifying opportunities for improvement, and promoting sign...

Purpose: To assess the impact of serum corrected calcium (CorrCa), magnesium (Mg) and phosphorus (P) levels at hospital admission on SARS-CoV-2 infection outcome.Methods: In this retrospective study, all adult patients with laboratory-confirmed COVID-19 hospitalized in Hospital Universitario Puerta de Hierro Madadahonda during 2020 were included. Demographic, clinical and laboratory data were registered and related to the prognosis of the disease. Poor o...

Introduction: Alemtuzumab is a monoclonal antibody targeting the CD52 glycoprotein, which is expressed by most mature leucocytes. In early relapsing-remitting multiple sclerosis (MS) alentuzumab effectively decreases relapse rate and disability progression. However, nearly 50% of the pacients treated with alentuzumab develop secondary autoimmune disorders, being Graves’ disease the most common. The development of thyroid eye disease is unusual.Aims ...